|Anti-hCD20-hIgA2||Unit size||Cat. code||Docs||Qty||Price|
Human CD20 (rituximab) antibody - Human IgA2
Monoclonal human IgA2 antibody against human CD20
Anti-hCD20-hIgA2 features the constant region of the human IgA2 isotype and the variable region of rituximab.
Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.
Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.
Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.
Anti-hCD20-hIgA2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.
Comparison of ADCC potency for native and engineered anti-human CD20 antibody isotypes: Raji-Null cells were incubated with gradient concentrations of Anti-hCD20 or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with targets cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown
Clonality: Monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgA2, kappaBack to the top
- 100 µg purified anti-hCD20-hIgA2 antibody, provided azide-free and lyophilized.
Product is shipped at room temperature.
Store lyophilized antibody at -20°C.
Lyophilized product is stable for 1 year.Back to the top